33c share price target by July 2021, page-254

Hi @T.E.P.,

I valued your previous methodical contributions.
Would like to know your sentiment/opinion if you have any, given the recent advancements on BOT.

Namely Sofpironium Bromide purchase and advancements in BTX1801, BTX1702 and renewed BTX1204A in dogs.
I've collated some information if you are not following BOT.


(Edit: Sofpironium Bromide has been submitted)

It seems like BOT is advancing towards the business end of the stick, where announcements are sparse due to longer trials and a now concentrated portfolio. Daily prices are just white noise and rerates will only occur based on results.

Sofpironium Bromide
- Expected $130M of sales in the U.S within the first year.
-FDA approval (Decision) expected within the next 12 months

EurozHartleys report below.
https://botanixpharma.com/wp-content/uploads/BOT-Note_17Aug22.pdf

BTX1503
BTX1503 Ph2 issues where highlighted by EurozHartleys.


.....


On this note, they are waiting for positive data from BTX1702, which will allow for a significantly higher concentration dosage to be applied in Ph3.

https://botanixpharma.com/wp-content/uploads/Euroz-Hartleys.pdf

BTX1801
-Successful Ph2a Trial
-Planned Ph2b - Ethics approval submitted
-Current target is Staph in Haemodialysis patients, due to the large sample size and easy to acquire participants.


BTX1702
-Data readout of Ph2b shortly
-Hopefully data will show improved concentration levels = greater efficacy
-This trial in my opinion is a massive de-risk if successful, as management have held off of the planning BTX1503 Ph3
-Also note that this study will provide some endpoint assessments quality control and consistency.

BTX1204A
-Completion of trial soon
-Looking for a follow up study with larger canines before finally human trials again
-Trial also used to assist in development of a new delivery system of Permetrex

EurozHartleys note that the previous failure may have been due to concentration levels



Once again, looking forward to your opinion.
Cheers